MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame (sORF) within the mitochondrial 12S rRNA gene. ^(1,2) It belongs to a newly discovered class of bioactive molecules called mitochondrial-derived peptides (MDPs), which also includes humanin and the SHLP family of peptides. What makes MDPs remarkable is that they are encoded by mitochondrial DNA, not the nuclear genome, meaning they represent a previously unknown channel of communication from the mitochondria to the rest of the cell and body. ⁽¹⁾

MOTS-c was discovered in 2015 by a research team led by Changhan Lee at the Pinchas Cohen laboratory at the University of Southern California, Davis School of Gerontology. ⁽¹⁾ The discovery emerged from genetic and pharmacological screening of metabolic regulators in human cells and represented a paradigm shift in how scientists understand mitochondrial function: mitochondria are not merely energy-producing organelles but active signaling hubs that encode and release peptide hormones (mitokines) influencing systemic metabolism. ^(1,2)

The peptide is highly conserved across species, suggesting an evolutionarily important biological function. ⁽¹⁾ Under conditions of metabolic stress or exercise, MOTS-c is released from mitochondria and translocates to the cell nucleus, where it regulates the expression of nuclear genes involved in stress adaptation and antioxidant responses, particularly those containing antioxidant response elements (ARE). ^(2,3) This mitochondrial-to-nuclear communication pathway is the basis for MOTS-c’s broad metabolic effects.

MOTS-c has been termed an “exercise mimetic” because exogenous administration in animal models reproduces many of the cellular and metabolic adaptations that normally occur in response to physical exercise, including enhanced glucose metabolism, improved insulin sensitivity, increased fat oxidation, and improved physical endurance. ^(1,4) Endogenous MOTS-c levels increase approximately 11.9-fold in skeletal muscle following exercise and 1.6-fold in circulation, returning to baseline within 4 hours. ⁽⁴⁾

MOTS-c is not FDA-approved for any therapeutic indication. The FDA has listed MOTS-c among bulk drug substances that are ineligible for use in compounding medications due to insufficient human safety data. ⁽⁵⁾ WADA prohibits it under Section S4.4.1 (Metabolic Modulators: Activators of AMP-activated protein kinase) at all times. ⁽⁶⁾ Healius supplies MOTS-c as a lyophilized (also referred to as lyophilized) powder in 10mg vials, intended strictly for laboratory and research applications.

MOTS-c exerts its metabolic effects primarily by robustly activating 5′-AMP-activated protein kinase (AMPK), often described as the cell’s master energy sensor and metabolic switch. ^(1,2,3)

The mechanistic pathway was elucidated in the original 2015 discovery by Lee et al. through global unbiased metabolomic profiling. ⁽¹⁾ MOTS-c targets the folate-methionine cycle and the directly connected de novo purine biosynthesis pathway. Treatment with MOTS-c decreases levels of 5-methyltetrahydrofolate (5Me-THF) and methionine, while increasing homocysteine, with disruption of the folate cycle occurring first. ⁽¹⁾ The downstream consequence is blockage of de novo purine biosynthesis, which elevates intracellular levels of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). ^(1,3) AICAR is a well-established AMPK activator: it is phosphorylated by cellular kinases to form ZMP, which acts as an AMP mimetic that directly binds and activates AMPK. This Folate-AICAR-AMPK pathway is the primary mechanism through which MOTS-c influences cellular energy homeostasis. ^(1,3)

AMPK activation by MOTS-c triggers a cascade of metabolic effects. In skeletal muscle, AMPK enhances glucose uptake by promoting GLUT4 transporter translocation to the cell membrane, increases fatty acid oxidation, and shifts cellular metabolism toward catabolic (energy-producing) pathways. ^(3,7) These are the same metabolic adaptations that occur during exercise, which is why MOTS-c is classified as an exercise mimetic. In the liver, AMPK activation suppresses gluconeogenesis and lipogenesis, thereby improving whole-body glucose and lipid homeostasis. ⁽³⁾

Beyond AMPK, MOTS-c binds to casein kinase 2 (CK2), though the functional significance of this interaction remains to be characterized (also spelled characterized). ⁽¹⁾ Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it regulates the expression of genes with antioxidant response elements (ARE), providing a direct link between mitochondrial status and nuclear gene expression. ^(2,3) This retrograde signaling mechanism is unique to mitochondrial-derived peptides and represents a fundamentally different mode of cellular regulation compared to conventional peptide hormones.

The parallels between MOTS-c and metformin are notable. Both activate AMPK, and both improve insulin sensitivity and glucose metabolism. ⁽³⁾ However, MOTS-c and metformin have different primary sites of action: MOTS-c acts predominantly in skeletal muscle, while metformin acts predominantly in the liver. ⁽³⁾ Whether their side effect profiles would also differ remains to be established in human clinical studies.

The metabolic effects of MOTS-c have been extensively studied in preclinical models, with consistently positive findings across multiple research groups and disease models. No large-scale human clinical trials of native MOTS-c have been completed. ^(5,8)

In the foundational 2015 study, Lee et al. demonstrated that exogenous administration of MOTS-c prevented diet-induced obesity and insulin resistance in mice fed a high-fat diet. ⁽¹⁾ Notably, MOTS-c treatment delayed weight gain without affecting food intake, suggesting that the peptide directly increases whole-body metabolic rate rather than suppressing appetite. ⁽¹⁾ This finding has been replicated across multiple subsequent studies in obesity models. ⁽⁸⁾

Insulin sensitivity research has shown that MOTS-c improves glucose metabolism in skeletal muscle by activating AMPK and promoting GLUT4 translocation. ^(1,3) Circulating MOTS-c levels are reduced in individuals with type 2 diabetes, gestational diabetes, coronary endothelial dysfunction, and obese male children/adolescents, suggesting an endogenous protective role that is compromised in metabolic disease. ^(8,9) A 2024 systematic review and meta-analysis confirmed that plasma MOTS-c levels are inversely correlated with markers of metabolic dysfunction, including fasting insulin, glycated hemoglobin (also spelled hemoglobin), and body mass index. ⁽⁹⁾

A 2025 study published in Frontiers in Physiology demonstrated that MOTS-c treatment effectively restored mitochondrial respiration in a type 2 diabetic heart model, providing the first evidence that MOTS-c can rescue cardiac mitochondrial dysfunction in diabetes. ⁽⁸⁾ This is significant because heart failure is the primary cause of premature death among type 2 diabetes patients, and mitochondrial dysfunction in the diabetic heart is a major contributor to reduced cardiac contractile performance. ⁽⁸⁾

The MOTS-c analog CB4211, developed by CohBar Inc., completed a Phase 1a/1b clinical trial (NCT03998514) in 20 obese patients with nonalcoholic fatty liver disease. ⁽¹⁰⁾ Participants received 25 mg CB4211 via subcutaneous injection daily for 28 days. The study met its primary safety endpoint: CB4211 was well tolerated, with significant reductions in liver enzymes (ALT) and glucose levels, plus a trend toward weight loss. ⁽¹⁰⁾ While this is a MOTS-c analog rather than native MOTS-c, it provides the closest available human clinical data for this class of mitochondrial-derived peptide therapeutics. No further clinical development of CB4211 has been announced as of 2026.

Regarding the frequently searched “before and after” query: no standardized human before-and-after data are available for native MOTS-c. The preclinical metabolic data summarised above, and the CB4211 Phase 1b results, represent the most reliable published evidence base.

The classification of MOTS-c as an exercise mimetic is supported by convergent evidence from both endogenous expression studies and exogenous administration experiments. ^(1,4)

Research by Reynolds et al. ⁽²⁰²¹⁾, published in Nature Communications, demonstrated that endogenous MOTS-c levels increase approximately 11.9-fold in skeletal muscle following exercise, with circulating levels increasing 1.6-fold during exercise and 1.5-fold post-exercise before returning to baseline within 4 hours. ⁽⁴⁾ This exercise-induced expression profile mirrors that of other exercise-responsive molecules like irisin and lactate, positioning MOTS-c as part of the body’s natural exercise adaptation signaling network.

In the same 2021 study, exogenous MOTS-c administration to aged mice produced remarkable performance improvements: old mice treated with MOTS-c doubled their treadmill running time and outperformed untreated middle-aged comparators. ⁽⁴⁾ The treated aged mice showed rejuvenated muscle phenotypes, including improved metabolic flexibility, enhanced glucose utilization, and reduced markers of muscle aging. ⁽⁴⁾ These findings suggest that MOTS-c may counteract age-related declines in muscle function by restoring the metabolic adaptations that normally occur with exercise but diminish with aging (also spelled aging).

The longevity connection is compelling. A study by Fuku et al. ⁽²⁰¹⁵⁾ identified specific mitochondrial DNA variants in the region encoding MOTS-c that were associated with exceptional longevity in a Japanese population, suggesting that MOTS-c may be involved in the molecular mechanisms underlying human lifespan variation. ⁽¹¹⁾ Circulating MOTS-c levels decline with age, paralleling the decline in mitochondrial function that characterizes biological aging. ^(2,3)

In metabolic research, MOTS-c’s exercise-mimetic properties have implications beyond physical performance. Exercise is the single most effective intervention for preventing and managing metabolic syndrome, type 2 diabetes, cardiovascular disease, cognitive decline, and sarcopenia. A compound that activates overlapping cellular pathways could serve as a research tool to identify which specific exercise-induced adaptations are responsible for each clinical benefit and whether pharmacological activation of those pathways can substitute for or complement physical activity in populations unable to exercise adequately. ⁽⁴⁾

MOTS-c and SS-31 (elamipretide) are both classified as mitochondrial peptides, but they are mechanistically distinct compounds that should not be considered interchangeable in research protocols. ⁽¹²⁾

MOTS-c is a mitochondrial-derived peptide (MDP) encoded by mitochondrial DNA. It acts through the Folate-AICAR-AMPK pathway, exerting its effects primarily on cellular energy metabolism, glucose regulation, and exercise-like metabolic adaptations in skeletal muscle. ^(1,3) Its mechanism is metabolic and gene-regulatory: MOTS-c translocates to the nucleus and modulates gene expression under stress conditions.

SS-31 (also known as elamipretide, Bendavia, or MTP-131) is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that is not encoded by mitochondrial DNA. It acts by binding to cardiolipin on the inner mitochondrial membrane, stabilizing membrane structure and optimizing electron transport chain function. ⁽¹²⁾ Its mechanism is structural and bioenergetic: SS-31 directly improves mitochondrial membrane integrity and ATP production efficiency.

The practical distinction for researchers: MOTS-c is positioned for metabolic and performance adaptation research, targeting AMPK-mediated glucose metabolism, insulin sensitivity, and exercise mimicry. SS-31 is positioned for research on mitochondrial membrane dysfunction, targeting bioenergetic efficiency, oxidative stress, and conditions involving primary mitochondrial impairment. Some research protocols explore combining both compounds to address mitochondrial function from complementary angles, though published combination data are limited.

Both MOTS-c and SS-31 are WADA-prohibited. MOTS-c falls under S4.4.1 (AMPK activators), and SS-31 is classified under S0 (Non-Approved Substances). Neither is FDA approved for any indication, though SS-31/elamipretide has progressed further in human clinical trials for Barth syndrome and primary mitochondrial myopathy. ⁽¹²⁾

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.

2. Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism, and aging. Journal of Translational Medicine. 2023; 21:36. PMC9854231.

3. Frontiers in Endocrinology. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. 2023. PMC9905433. Review of Folate-AICAR-AMPK pathway, metabolic regulation, and therapeutic applications.

4. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021; 12:470. (11.9-fold skeletal muscle increase, doubled treadmill time in aged mice.)

5. USADA. What is the MOTS-c peptide? January 2024. FDA classification, compounding restrictions, safety concerns, and WADA status overview.

6. World Anti-Doping Agency. WADA Prohibited List 2024-2026. MOTS-c prohibited under S4.4.1: Metabolic Modulators, Activators of AMP-activated protein kinase (AMPK)—all times.

7. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation. 2006;116(7):1776-1783.

8. Pham T, Taberner AJ, Hickey AJR, Han JC. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic hearts. Frontiers in Physiology. 2025; 16:1602271.

9. Zhou Q, et al. The correlation between mitochondrial-derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024; 16:200. PMC11331736.

10. CohBar Inc. CB4211 Phase 1a/1b topline results. NCT03998514. 20 obese patients with NAFLD, 25mg CB4211 SubQ daily for 28 days. Well tolerated, reductions in ALT and glucose. 2021.

11. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015;14(6):921-927.

12. SS-31 (elamipretide): synthetic tetrapeptide targeting cardiolipin on the inner mitochondrial membrane. Mechanistically distinct from MOTS-c. Clinical trials for Barth syndrome and primary mitochondrial myopathy.

13. Community-based MOTS-c dosing protocols: 5-10mg subcutaneous injection, 3-5x weekly. PeptideDosingProtocols.com and PeptideWiki compiled dosing references. February 2026.

14. Mohtashami Z, Singh MK, Taye N, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. International Journal of Molecular Sciences. 2022;23(19):11991. (Stability: no significant degradation at 4 °C for 30 days.)

15. Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and are associated with insulin resistance. Pediatric Diabetes. 2018;19(6):1058-1064.

16. Scientific Reports. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. 2021. Nature. (Exercise intervention increased MOTS-c levels in non-Hispanic White breast cancer survivors.)

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.